Investor information
Building pharmaceutical infrastructure from one focused product
NEUVIOR is building an integrated pharmaceutical company from a focused first product. PHARMORIS addresses the gap between evidence, decision, ownership and governed execution.
INVESTOR CONTEXT / PUBLIC RECORD
External context and project support record. This is not company performance.
Founder thesis
The investment case begins with proving institutional demand for a focused workflow before widening the company.
Investment thesis
Begin with the operating gap institutions must solve.
PHARMORIS is intended to help authorised medicines teams move from evidence and prioritisation to accountable ActionCases, governed decisions, activity, blocker management and review.
The immediate commercial test is whether institutional buyers confirm the problem, pay to evaluate the workflow and accept the value model.
Problem
Evidence does not reliably become owned and reviewable action.
Focused product
One configurable, human governed medicines operations product.
Expansion
Adjacent pharmaceutical capability only after the first product is repeatable.
Commercial discipline
Progress depends on paid evidence, not presentation.
NEUVIOR intends to avoid unpaid pilots and customer specific product forks. An evaluation should be paid, time limited, governed and linked to a defined contracting decision.
Buyer confirmation
The responsible institution recognises the problem and intended value.
Continue conditionPaid evaluation
The scope, evidence, decision date and success measures are explicit.
Continue conditionRepeatable delivery
Configuration and assurance can be reused without a customer specific fork.
Scale conditionProduct evidence
See what is built. See what still needs proving.
PHARMORIS is NEUVIOR's current commercial focus. The controlled Demo40 workflow shows how public source evidence can become a source linked ActionCase, a named human review and an auditable record.
The purpose is not to automate authority. It is to make the next decision easier to inspect, challenge and govern.
Controlled Demo40 snapshot
A dated product evidence ledger.
Reviewed 4 August 2026
The demonstration source timestamp is 16 July 2026. These counts are not production performance measures.
- 3
- Source linked ActionCases
- 3
- Evidence rows linked
- 8
- Linked evidence items
- 3
- Human reviews required
- 0
- Patient data feeds
- 0
- Realised value evidence
Source qualification
A source becomes useful only after it becomes governable.
Discovery is the start of diligence. It is not evidence of an integration. Every future source should pass a visible sequence before it can support live work.
- 01
Candidate source research
Identify a potentially relevant source without treating discovery as permission or connectivity.
- 02
Rights and access check
Confirm the rights, licence, lawful basis and technical route needed for the intended use.
- 03
Source receipt
Record what arrived, when it arrived, its scope and any material limitation.
- 04
ActionCase
Create governed work only when the source, assumptions and decision need remain visible.
- 05
Named human review
Name the accountable reviewer. Keep the decision with an authorised person.
- 06
Audit record
Preserve the source, review state and decision history for later inspection.
Next proof
The questions that should determine what comes next.
- 01
Will a responsible buyer fund a time limited operational test?
- 02
Can the workflow be configured without a customer specific product fork?
- 03
Can the buyer validate value, safety and implementation evidence locally?
- 04
Does the test progress to repeat procurement?
Risk boundary
What the public record supports. What remains to prove.
| Area | What the public record supports | What remains to prove |
|---|---|---|
| Product | A controlled source linked demonstration with human review. | Production readiness and independent assurance. |
| Commercial | A defined route from product review to a paid evaluation decision. | A signed buyer contract and repeat procurement. |
| Value | Projected opportunities remain visibly labelled as projected. | Independently reviewed evidence of realised value. |
| Data | Public source evidence and zero patient data feeds in the controlled demonstration. | Approved and lawful data access for any future live scope. |
| Expansion | PHARMORIS is NEUVIOR's current product focus. | Evidence that supports investment in each later capability. |
PUBLIC DATA / SOURCE CHECKED 20 JULY 2026
Investor context and public record
External context and project support record. This is not company performance.
FIGURE A / NHSBSA
Estimated cost to NHS commissioners before central rebates
England, calendar years 2020 to 2025
Line chart showing the NHSBSA England total increasing from £16.15bn in 2020 to £22.16bn in 2025.
Sources: NHSBSA publicationNHSBSA statistical summary workbook
| Year | Exact GBP | Display |
|---|---|---|
| 2020 | 16,150,103,693.7714 | £16.15bn |
| 2021 | 17,504,726,814.6583 | £17.50bn |
| 2022 | 18,481,660,799.5121 | £18.48bn |
| 2023 | 20,221,015,312.1001 | £20.22bn |
| 2024 | 21,255,229,398.1745 | £21.26bn |
| 2025 | 22,162,066,435.2205 | £22.16bn |
FIGURE B / NHSBSA
Estimated cost by prescribing and dispensing setting
England, calendar year 2025
Comparison showing £11.43bn for Hospital prescribing issued within hospitals and £10.56bn for Primary care prescribing dispensed in the community, with three smaller settings listed separately.
Sources: NHSBSA publicationNHSBSA statistical summary workbook
| Setting | Exact GBP | Display |
|---|---|---|
| Hospital prescribing issued within hospitals | 11,429,956,273.5705 | £11.43bn |
| Primary care prescribing dispensed in the community | 10,558,085,676.11 | £10.56bn |
| Hospital prescribing dispensed in the community | 111,117,697.31 | £111.1m |
| Dental prescribing dispensed in the community | 35,143,788.23 | £35.1m |
| Adult Secure Estate | 27,763,000 | £27.8m |
FIGURE C / OLS
UK life sciences subsector context
Office for Life Sciences estimates, 2023/24
Three paired comparisons showing biopharmaceutical and medical technology turnover, employment and company counts in the Office for Life Sciences 2023/24 estimates.
Source: Office for Life Sciences source
| Measure | Biopharmaceutical | Medical technology |
|---|---|---|
| Turnover | £98.9bn | £48.0bn |
| Employment | 163,600 | 196,000 |
| Companies | 2,960 | 4,360 |
FIGURE D / PROJECT SUPPORT
Support without equity dilution
Source linked project support ledger. No aggregate funding total is presented. Published award values, eligible project costs, company contributions and cash received remain distinct.
Source linked project support with no aggregate funding claim
NEUVIOR disclosure: Project support record
| Funding component | Provider and basis | Published value | Status | Source |
|---|---|---|---|---|
| VIONIX ZERO | Innovate UK · Published grant award | £25,000 | Awarded | UKRI project 10180575 |
| PHARMORIS | Innovate UK · Published grant award | £49,928 | Awarded | UKRI project 10173524 |
| SMART:SCOTLAND | Scottish Enterprise · Published reporting | Publicly reported support | Publicly reported | TheBusinessDesk.com public award record |
External context is not NEUVIOR market size, traction, revenue, customers, deployment, adoption, savings or outcomes.
- Podcast appearance. AI Ethics Now / University of Warwick IATL. AI and Accountability: When Does a Suggestion Become a Decision?. 23 August 2026.
- Contributed analysis. Pharmaphorum. Approval is not access: Pilots' real test is implementation. 18 August 2026.
- Contributed opinion. TechRadar Pro. Five questions to test whether an AI stack is truly under your control. 11 August 2026.
- Founder commentary. ET Pharma. India’s pharma quality reset will be won after the inspector leaves. 4 August 2026.
- NEUVIOR analysis. NEUVIOR Founder Reflections. From invention to adoption: the work between. 3 August 2026.
- NEUVIOR analysis. NEUVIOR Founder Reflections. A trade deal is not a patient pathway. 3 August 2026.
- NEUVIOR analysis. NEUVIOR Insights. NHS digital programmes do not fail on dashboards. They fail on deployment. 20 March 2026.
- Founder viewpoint. Pharmaceutical Technology. Why the India UK trade deal now needs a five gate implementation ledger. 28 July 2026.
- Release derived reporting. TheBusinessDesk.com. NEUVIOR company support coverage. 19 May 2026.
- Founder commentary. Startups Magazine. What my dad's corner shop taught me. 6 May 2026.
- Expert commentary. Manufacturing Chemist. NICE approval is not enough: why the UK's next medicines challenge is operational delivery. 4 June 2026.
- Founder commentary. PharmaTimes. How we roll. 10 June 2026.
- Founder commentary. BusinessCloud. Why neurodivergent founders can excel at building complex systems. 18 March 2026.
- Partner announcement. Biorenewables Development Centre. NEUVIOR research record. 20 April 2026.
Classified public record
OPPORTUNITY + PUBLIC EVIDENCE
Read the opportunity. Then inspect the evidence.
The analysis explains why the medicines opportunity matters. The public record shows dated support and publication, not revenue, product adoption or realised value.
What feasibility support should actually buy
Support matters when it converts expensive uncertainty into a clearer product, technical, commercial or stop decision.
See what early support should actually buyNHS digital programmes do not fail on dashboards. They fail on deployment
The NHS does not lack medicines dashboards. It lacks enough tools that turn those signals into action. That distinction matters because many digital programmes in medicines still behave as though visibility is the scarce resource.
Understand the implementation gapNEUVIOR company support coverage
Scottish regional business coverage recording publicly reported SMART:SCOTLAND support for NEUVIOR.
Open the classified Scottish company record
NEUVIOR Insights and After Publication reflections are company or founder analysis. Publisher records evidence publication, not endorsement, adoption, product readiness, savings or clinical outcomes.
Make the next step useful
Bring the problem that needs a clearer decision.
Tell us what is stuck, what decision you need to make and what a better outcome would change. We will connect you to the most relevant NEUVIOR, PHARMORIS, media or investor route.